Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq
Other stock markets
 04:00:02 2024-04-18 pm EDT 		5-day change 1st Jan Change
37.82 USD -0.53% Intraday chart for Halozyme Therapeutics, Inc. -3.81% +2.33%
Apr. 18 Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT
Mar. 13 Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing MT

Evolution of the average Target Price on Halozyme Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2.4NBm-TLsqM1V3uwUu7FrWzaPNmYnBVDYcBw5WQ8j4pE.zZ8tigaPy4wjnN1i4_BdOFe-GzlAbDO9Hl9OD0t316ilsiW8ZN3N_R6qtQ~a54b52057d95ab403eba3812a7d0e6b0

Analyst Recommendations on Halozyme Therapeutics, Inc.

Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing MT
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating MT
Goldman Sachs Cuts Halozyme Therapeutics' Price Target to $40 From $45, Keeps Neutral Rating MT
HC Wainwright Cuts Halozyme Therapeutics Price Target to $48 From $61, Maintains Buy Rating MT
Morgan Stanley Cuts Halozyme Therapeutics Price Target to $59 From $61, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $61 From $60, Keeps Overweight Rating MT
Goldman Sachs Downgrades Halozyme Therapeutics to Neutral From Buy, Raises Price Target to $45 From $43 MT
HC Wainwright Starts Halozyme Therapeutics at Buy With $61 Price Target MT
Morgan Stanley Adjusts Price Target on Halozyme Therapeutics to $60 From $64, Maintains Overweight Rating MT
Piper Sandler Upgrades Halozyme Therapeutics to Overweight From Neutral With $46 Price Target MT
Berenberg Bank Resumes Coverage on Halozyme Therapeutics With Buy Rating, $58 Price Target MT
Wells Fargo Adjusts Price Target on Halozyme Therapeutics to $48 From $55, Maintains Overweight Rating MT
Wells Fargo Adjusts Halozyme Therapeutics' Price Target to $55 From $65, Keeps Overweight Rating MT
SVB Securities Downgrades Halozyme Therapeutics to Market Perform From Outperform, Price Target is $42 MT
Morgan Stanley Adjusts Halozyme Therapeutics Price Target to $64 From $65, Maintains Overweight Rating MT
JPMorgan Adjusts Price Target on Halozyme Therapeutics to $52 From $54, Maintains Overweight Rating MT
JMP Securities Adjusts Price Target on Halozyme Therapeutics to $66 From $62, Maintains Market Outperform Rating MT
Morgan Stanley Assumes Halozyme Therapeutics at Overweight Rating, Adjusts Price Target to $65 From $53 MT
Benchmark Adjusts Price Target on Halozyme Therapeutics to $68 From $55, Maintains Buy Rating MT
Halozyme Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight MT
Wells Fargo Starts Halozyme Therapeutics at Overweight With $65 MT
JPMorgan Chase Adjusts Price Target on Halozyme Therapeutics to $54 From $53, Maintains Overweight Rating MT
JMP Securities Adjusts Price Target on Halozyme Therapeutics to $62 From $60, Maintains Market Outperform Rating MT
Morgan Stanley Initiates Halozyme Therapeutics at Overweight Rating With $50 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
37.82 USD
Average target price
50.7 USD
Spread / Average Target
+34.06%
High Price Target
72 USD
Spread / Highest target
+90.38%
Low Price Target
39 USD
Spread / Lowest Target
+3.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Halozyme Therapeutics, Inc.

HC Wainwright
Goldman Sachs
Morgan Stanley
Piper Sandler
Berenberg Bank
Wells Fargo Securities
SVB Securities LLC
JPMorgan Chase
JMP Securities
Benchmark Company
SVB Leerink
Evercore ISI
Benchmark Capital

Ratings for Halozyme Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HALO Stock
  4. Consensus Halozyme Therapeutics, Inc.